Introduction

 The launch of a new diabetes treatment in Latin America represents a crucial challenge for pharmaceutical companies. In this case, a renowned global company partnered with Pro Pharma Research Organization to introduce an innovative treatment in Mexico and Brazil. As they faced strict regulations and a competitive market, the focus on clinical effectiveness and economic justification became essential for achieving market access and reimbursement.

Overview

A global pharmaceutical company partnered with Pro Pharma Research Organization to introduce a novel diabetes treatment in Mexico and Brazil. The company faced significant challenges, including navigating strict health technology assessments (HTA), addressing concerns about cost-effectiveness, and competing in a crowded market. The objective was to secure market access and favorable reimbursement while demonstrating the clinical and economic value of the drug to local payers.

Objectives

• Secure market access and reimbursement for the new diabetes treatment in Mexico and Brazil.
• Demonstrate the long-term cost-effectiveness of the product.
• Influence decision-makers and local stakeholders to adopt the treatment.

Strategy

PPRO implemented a multi-faceted advocacy campaign combining scientific data and regional insights. Key elements included:

• Evidence-Based Value Propositions: PPRO worked closely with the pharmaceutical company to generate a robust clinical dossier that demonstrated the treatment's effectiveness in reducing diabetes complications, hospitalizations, and overall healthcare costs. The campaign highlighted long-term benefits that aligned with payers' priorities.
• Engagement with Key Opinion Leaders (KOLs): PPRO collaborated with influential KOLs in the region to present the treatment's clinical value in conferences, advisory boards, and publications. These experts helped build trust and credibility around the product.
• Real-World Evidence (RWE): PPRO supported post-launch real-world evidence generation to continuously demonstrate the drug's impact on patients’ health outcomes. The organization collected data on reduced hospital admissions and cost savings, strengthening the reimbursement case.
• Tailored Communication for Local Stakeholders: PPRO’s Scientific Advocacy services in Mexico, Brazil, and LATAM developed region-specific strategies that addressed local market dynamics, including tailored messaging for different stakeholders such as healthcare professionals, payers, and patient advocacy groups.

Results

• Market Access Achieved: The treatment received approval and was successfully introduced in Mexico and Brazil.
• Favorable Reimbursement Decisions: Both countries’ payers recognized the long-term cost savings, resulting in positive reimbursement outcomes.
• Stakeholder Support: The engagement of local KOLs and the generation of real-world data ensured continuous support from healthcare providers and policymakers.
• Increased Patient Access: The treatment became widely available in the public and private healthcare sectors in both countries, improving diabetes management and reducing complications.

Conclusion

The launch of a new diabetes treatment in Mexico and Brazil, conducted by a global pharmaceutical company in collaboration with Pro Pharma Research Organization, overcame regulatory and market challenges. Through clinical evidence, collaboration with key opinion leaders, and tailored communication, they secured product approval and reimbursement. As a result, the treatment improved diabetes management and increased patient access, highlighting the importance of a comprehensive strategy in emerging markets.

Contact us and discover how our Scientific Advocacy Services can enhance the success of your project in LATAM!

contacto@propharmaresearch.com